MK1022-016: An Open-label Randomized Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician�s Choice in Hormone Receptor-positive HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
